This article has been updated from an earlier version.
NEW YORK, Oct. 8 (GenomeWeb News) - Ebersberg, Germany-based MWG Biotech today said that it plans to divest its microarray and lab automation businesses.
In a statement, the company said that managment will consider "various separation" options for the divestiture of the product lines to focus on its genomic synthesis business, the production of synthetic nucleic acids and oligonucleotides, and genomic information (DNA sequencing).
The company said it expects a negative impact on its financials, but was not able to provide any specific guidance, but said it will seek new capital.
MWG was founded in 1990 and added its genomic diagnostics (microarrays) division in 2000.